Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
SEC Accession No. 0002005369-26-000002
Filing Date
2026-01-27
Accepted
2026-01-27 14:18:24
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 16605
2 JOINT FILING AGREEMENT exhibit991.htm EX-99.1 6644
  Complete submission text file 0002005369-26-000002.txt   25004
Mailing Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1
Business Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1 (514) 332-4888
enGene Holdings Inc. (Subject) CIK: 0001980845 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1031
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94211 | Film No.: 26564201
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address THE INVUS GROUP, LLC 750 LEXINGTON AVENUE, 30TH FLOOR NEW YORK NY 10022
Business Address THE INVUS GROUP, LLC 750 LEXINGTON AVENUE, 30TH FLOOR NEW YORK NY 10022 212-371-1717
Invus Global Management, LLC (Filed by) CIK: 0002005369 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G